HNF1B polymorphism influences the prognosis of endometrial cancer patients: A cohort study

Vincenzo Dario Mandato, Enrico Farnetti, Federica Torricelli, Martino Abrate, Bruno Casali, Gino Ciarlini, Debora Pirillo, Maria Carolina Gelli, Davide Nicoli, Mario Grassi, Giovanni Battista la Sala, Stefano Palomba

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: HNF1B (formerly known as TCF2) gene encodes for a transcription factor that regulates gene expression involved in normal mesodermal and endodermal developments. A close association between rs4430796 polymorphism of HNF1B gene and decreased endometrial cancer (EC) risk has been demonstrated. The aim of the current study was to test the hypothesis that rs4430796 polymorphism can influence the prognosis of EC patients. Methods: Retrospective cohort study. Clinical and pathological data were extrapolated and genotypes were assessed on formalin-fixed and paraffin-embedded non-tumour tissues. The influence of patients' genotype on overall survival and progression free survival were our main outcome measures. Results: A total of 191 EC patients were included in the final analysis. Overall survival differed significantly (P = 0.003) among genotypes. At multivariate analysis, a significant (P <0.05) effect on overall survival was detected for FIGO stage, and rs4430796 polymorphism of HNF1B gene. After grouping EC patients according to adjuvant treatment, rs4430796 polymorphism resulted significantly (P <0.001) related to overall survival only in subjects who received radiotherapy plus chemotherapy. A significant (P = 0.014) interaction between rs4430796 polymorphism and chemo-radiotherapy was also detected. Finally, only a trend (P = 0.090) towards significance was observed for rs4430796 polymorphism effect on progression free survival. Conclusions: rs4430796 polymorphism of HNF1B gene influences independently the prognosis of EC patients with a potential effect on tumor chemo-sensitivity.

Original languageEnglish
Article number229
JournalBMC Cancer
Volume15
Issue number1
DOIs
Publication statusPublished - Apr 7 2015

Fingerprint

Endometrial Neoplasms
Cohort Studies
Survival
Genotype
Genes
Disease-Free Survival
Radiotherapy
Paraffin
Formaldehyde
Transcription Factors
Multivariate Analysis
Retrospective Studies
Outcome Assessment (Health Care)
Gene Expression
Drug Therapy
Neoplasms
Therapeutics

Keywords

  • Adjuvant therapy
  • Endometrial cancer
  • HNF1B
  • Rs4430796
  • SNP
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Cite this

HNF1B polymorphism influences the prognosis of endometrial cancer patients : A cohort study. / Mandato, Vincenzo Dario; Farnetti, Enrico; Torricelli, Federica; Abrate, Martino; Casali, Bruno; Ciarlini, Gino; Pirillo, Debora; Gelli, Maria Carolina; Nicoli, Davide; Grassi, Mario; la Sala, Giovanni Battista; Palomba, Stefano.

In: BMC Cancer, Vol. 15, No. 1, 229, 07.04.2015.

Research output: Contribution to journalArticle

Mandato, Vincenzo Dario ; Farnetti, Enrico ; Torricelli, Federica ; Abrate, Martino ; Casali, Bruno ; Ciarlini, Gino ; Pirillo, Debora ; Gelli, Maria Carolina ; Nicoli, Davide ; Grassi, Mario ; la Sala, Giovanni Battista ; Palomba, Stefano. / HNF1B polymorphism influences the prognosis of endometrial cancer patients : A cohort study. In: BMC Cancer. 2015 ; Vol. 15, No. 1.
@article{bbfa5752b0d64dd89873966a66041f6a,
title = "HNF1B polymorphism influences the prognosis of endometrial cancer patients: A cohort study",
abstract = "Background: HNF1B (formerly known as TCF2) gene encodes for a transcription factor that regulates gene expression involved in normal mesodermal and endodermal developments. A close association between rs4430796 polymorphism of HNF1B gene and decreased endometrial cancer (EC) risk has been demonstrated. The aim of the current study was to test the hypothesis that rs4430796 polymorphism can influence the prognosis of EC patients. Methods: Retrospective cohort study. Clinical and pathological data were extrapolated and genotypes were assessed on formalin-fixed and paraffin-embedded non-tumour tissues. The influence of patients' genotype on overall survival and progression free survival were our main outcome measures. Results: A total of 191 EC patients were included in the final analysis. Overall survival differed significantly (P = 0.003) among genotypes. At multivariate analysis, a significant (P <0.05) effect on overall survival was detected for FIGO stage, and rs4430796 polymorphism of HNF1B gene. After grouping EC patients according to adjuvant treatment, rs4430796 polymorphism resulted significantly (P <0.001) related to overall survival only in subjects who received radiotherapy plus chemotherapy. A significant (P = 0.014) interaction between rs4430796 polymorphism and chemo-radiotherapy was also detected. Finally, only a trend (P = 0.090) towards significance was observed for rs4430796 polymorphism effect on progression free survival. Conclusions: rs4430796 polymorphism of HNF1B gene influences independently the prognosis of EC patients with a potential effect on tumor chemo-sensitivity.",
keywords = "Adjuvant therapy, Endometrial cancer, HNF1B, Rs4430796, SNP, Survival",
author = "Mandato, {Vincenzo Dario} and Enrico Farnetti and Federica Torricelli and Martino Abrate and Bruno Casali and Gino Ciarlini and Debora Pirillo and Gelli, {Maria Carolina} and Davide Nicoli and Mario Grassi and {la Sala}, {Giovanni Battista} and Stefano Palomba",
year = "2015",
month = "4",
day = "7",
doi = "10.1186/s12885-015-1246-5",
language = "English",
volume = "15",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - HNF1B polymorphism influences the prognosis of endometrial cancer patients

T2 - A cohort study

AU - Mandato, Vincenzo Dario

AU - Farnetti, Enrico

AU - Torricelli, Federica

AU - Abrate, Martino

AU - Casali, Bruno

AU - Ciarlini, Gino

AU - Pirillo, Debora

AU - Gelli, Maria Carolina

AU - Nicoli, Davide

AU - Grassi, Mario

AU - la Sala, Giovanni Battista

AU - Palomba, Stefano

PY - 2015/4/7

Y1 - 2015/4/7

N2 - Background: HNF1B (formerly known as TCF2) gene encodes for a transcription factor that regulates gene expression involved in normal mesodermal and endodermal developments. A close association between rs4430796 polymorphism of HNF1B gene and decreased endometrial cancer (EC) risk has been demonstrated. The aim of the current study was to test the hypothesis that rs4430796 polymorphism can influence the prognosis of EC patients. Methods: Retrospective cohort study. Clinical and pathological data were extrapolated and genotypes were assessed on formalin-fixed and paraffin-embedded non-tumour tissues. The influence of patients' genotype on overall survival and progression free survival were our main outcome measures. Results: A total of 191 EC patients were included in the final analysis. Overall survival differed significantly (P = 0.003) among genotypes. At multivariate analysis, a significant (P <0.05) effect on overall survival was detected for FIGO stage, and rs4430796 polymorphism of HNF1B gene. After grouping EC patients according to adjuvant treatment, rs4430796 polymorphism resulted significantly (P <0.001) related to overall survival only in subjects who received radiotherapy plus chemotherapy. A significant (P = 0.014) interaction between rs4430796 polymorphism and chemo-radiotherapy was also detected. Finally, only a trend (P = 0.090) towards significance was observed for rs4430796 polymorphism effect on progression free survival. Conclusions: rs4430796 polymorphism of HNF1B gene influences independently the prognosis of EC patients with a potential effect on tumor chemo-sensitivity.

AB - Background: HNF1B (formerly known as TCF2) gene encodes for a transcription factor that regulates gene expression involved in normal mesodermal and endodermal developments. A close association between rs4430796 polymorphism of HNF1B gene and decreased endometrial cancer (EC) risk has been demonstrated. The aim of the current study was to test the hypothesis that rs4430796 polymorphism can influence the prognosis of EC patients. Methods: Retrospective cohort study. Clinical and pathological data were extrapolated and genotypes were assessed on formalin-fixed and paraffin-embedded non-tumour tissues. The influence of patients' genotype on overall survival and progression free survival were our main outcome measures. Results: A total of 191 EC patients were included in the final analysis. Overall survival differed significantly (P = 0.003) among genotypes. At multivariate analysis, a significant (P <0.05) effect on overall survival was detected for FIGO stage, and rs4430796 polymorphism of HNF1B gene. After grouping EC patients according to adjuvant treatment, rs4430796 polymorphism resulted significantly (P <0.001) related to overall survival only in subjects who received radiotherapy plus chemotherapy. A significant (P = 0.014) interaction between rs4430796 polymorphism and chemo-radiotherapy was also detected. Finally, only a trend (P = 0.090) towards significance was observed for rs4430796 polymorphism effect on progression free survival. Conclusions: rs4430796 polymorphism of HNF1B gene influences independently the prognosis of EC patients with a potential effect on tumor chemo-sensitivity.

KW - Adjuvant therapy

KW - Endometrial cancer

KW - HNF1B

KW - Rs4430796

KW - SNP

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84928016145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928016145&partnerID=8YFLogxK

U2 - 10.1186/s12885-015-1246-5

DO - 10.1186/s12885-015-1246-5

M3 - Article

AN - SCOPUS:84928016145

VL - 15

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 229

ER -